Live
- All those linked with Adani case close to Congress: Purandeswari
- AP image hit: Naidu
- SwarnaAndhra@2047
- A treasure trove of stories to come alive at Hawa Mahal
- Sports meet for police personnel commences
- Three persons admitted to hospital for diarrhea treatment
- First Star Outside Milky Way Captured: WOH G64 is 2,000 Times Larger Than the Sun
- Sikkim govt to constitute state Niti Ayog: CM Tamang
- CBI books Rajasthan narcotics inspector for Rs 3 lakh bribe
- Rajasthan bypolls: A tough contest between BJP and Congress
Just In
64 foreign envoys leave for Hyderabad to visit biotech companies developing COVID-19 vaccine
64 foreign envoys, who are scheduled to visit leading biotech companies - Bharat Biotech and Biological E - which are developing vaccines against the novel coronavirus, have left for Hyderabad.
New Delhi [India]: 64 foreign envoys, who are scheduled to visit leading biotech companies - Bharat Biotech and Biological E - which are developing vaccines against the novel coronavirus, have left for Hyderabad.
Sources said that this is the first such visit and it will be followed by visits to facilities in other cities.
It is in continuation of the COVID-19 briefing by the Ministry of External Affairs on November 6.
India is the world's largest vaccine manufacturer and has been contributing significantly to global efforts against COVID-19 pandemic.
Sources said there is a lot of interest in India's vaccine development efforts.
Prime Minister Narendra Modi has said that India's vaccine production and delivery capacity will be used to help all humanity in fighting this crisis.
He visited the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad and Serum Institute of India in Pune on November 28 to conduct an extensive review of the vaccine development and manufacturing process.
On November 30, he had virtual meetings with teams from Gennova Biopharmaceuticals Ltd Pune, Biological E Ltd Hyderabad and Dr Reddys Laboratories Ltd Hyderabad. The three teams are working on developing and manufacturing vaccine for COVID-19.
Bharat Biotech had on Monday applied for emergency use authorisation for its indigenously developed COVID-19 vaccine 'Covaxin' to Drugs Controller General of India (DCGI).
It is the second Indian company to apply for emergency use authorisation after the Serum Institute of India applied for such use for the vaccine developed by Oxford University and AstraZeneca.
© 2024 Hyderabad Media House Limited/The Hans India. All rights reserved. Powered by hocalwire.com